US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust SMID Growth Strength ETF

31.01

+0.58451.92%

Post-market: 30.83-0.1802-0.58%16:10 EST

Volume:242.00

Turnover:7.46K

Market Cap:27.91M

PE:- -

High:31.01

Open:30.83

Low:30.83

Close:30.43

52wk High:31.95

52wk Low:24.39

Shares:900.00K

Float Shares:900.00K

Volume Ratio:0.02

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum

Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Assessing Travere Therapeutics (TVTX) Valuation As FDA Extends FILSPARI Review For FSGS Approval

Simply Wall St.

Travere Stock Slips After FDA Delays Review Of Key Kidney Drug

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Akebia Announces Establishment of Rare Kidney Disease Pipeline

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

Dimerix Achieves Positive IDMC Review for Phase 3 FSGS Trial

A Look at Travere Therapeutics’s Valuation Following Positive Phase 3 FILSPARI Data in FSGS

Simply Wall St.

Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys

MT Newswires Live

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan

MT Newswires Live

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Dimerix's Market Value Falls Despite Full Funding, Record Licensing Deal, Euroz Says

MT Newswires Live

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

Benzinga_recent_news

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/FSGS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":31.0142,"timestamp":1770411600000,"preClose":30.4297,"halted":0,"volume":242,"hourTrading":{"tag":"盘后","latestPrice":30.834,"preClose":31.0142,"latestTime":"16:10 EST","volume":6,"amount":185.9168,"timestamp":1770412204323,"change":-0.1802,"changeRate":-0.00581,"amplitude":0},"delay":0,"changeRate":0.019208207770697656,"floatShares":900002,"shares":900002,"eps":0,"marketStatus":"Market Closed","change":0.5845,"latestTime":"02-06 16:00:00 EST","open":30.834,"high":31.0142,"low":30.834,"amount":7461.0868,"amplitude":0.005922,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":30.4297,"sharesOutstanding":900002,"nav":30.43,"aum":27387060.86,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.834,"preClose":31.0142,"latestTime":"16:10 EST","volume":6,"amount":185.9168,"timestamp":1770412204323,"change":-0.1802,"changeRate":-0.00581,"amplitude":0},"volumeRatio":0.023927702293276173},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":900002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.023927702293276173,"shares":900002,"dividePrice":0,"high":31.0142,"amplitude":0.005922,"preClose":30.4297,"low":30.834,"week52Low":24.39,"pbRate":"--","week52High":31.95,"institutionHeld":0,"latestPrice":31.0142,"eps":0,"divideRate":0,"volume":242,"delay":0,"ttmEps":0,"open":30.834,"prevYearClose":30.4325,"prevWeekClose":31.0101,"prevMonthClose":31.0101,"prevQuarterClose":30.4325,"fiveDayClose":31.0101,"twentyDayClose":31.4619,"sixtyDayClose":30.575},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609314064","title":"Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2609314064","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609314064?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:27","pubTimestamp":1770247675,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix Limited announced that CEO and Managing Director Dr Nina Webster will present at the Eu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-to-showcase-phase-3-fsgs-program-and-growth-strategy-at-euroz-hartleys-healthcare-forum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-to-showcase-phase-3-fsgs-program-and-growth-strategy-at-euroz-hartleys-healthcare-forum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","LU0029874061.USD","BK4179","XLV","LU0128526141.USD","FET","BK4588","FSGS","HCSG","LABU","BK4585","BK4137"],"gpt_icon":0},{"id":"2606871662","title":"Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606871662","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606871662?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:30","pubTimestamp":1769603400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Jan. 28, 2026  -- Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial.\"We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"With his track record of building comprehensive commercial organizations and successfully launching multiple therapeutics, Matt's leadership will be critical in our ambition to change what's possible for patients in need.\". \"I am excited to spearhead our launch readiness activities and guide our evolution into a commercial-stage company,\" said Matt Skel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU0868494617.USD","LU2279689827.SGD","VERA","LU0256863811.USD","IE00BJTD4V19.USD","LU0795875169.SGD","LU0726765562.USD","LU1430594728.SGD","BK4534","LU0795875086.SGD","BK4550","TACI","MCD","BK4566","LU1718418525.SGD","LU2347655156.SGD","BK4139","IE00BJJMRX11.SGD","LU0942090050.USD","LU1074936037.SGD","LU1035773651.USD","BK4209","BK4610","IE00B7KXQ091.USD","LU2133065610.SGD","IE00BJTD4N35.SGD","LU1585245621.USD","LU1069347547.HKD","BK4585","IE00BFSS8Q28.SGD","BK4539","IE0004445015.USD","BK4504","LU0868494708.USD","FSGS","IE00BJJMRY28.SGD","IE00BFSS7M15.SGD","LU1732799900.SGD","BK4588","BK4581","LU1244550221.USD","LU1244550494.USD","LU0912757837.SGD","LU1732800096.USD","LU1244550577.SGD","LU2347655073.USD"],"gpt_icon":0},{"id":"2606296107","title":"Assessing Travere Therapeutics (TVTX) Valuation As FDA Extends FILSPARI Review For FSGS Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2606296107","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606296107?lang=en_us&edition=fundamental","pubTime":"2026-01-26 11:21","pubTimestamp":1769397677,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) is back in focus after the FDA extended its review of the company’s supplemental filing for FILSPARI in focal segmental glomerulosclerosis, following new data submissions to better clarify clinical benefit.\nSee our latest analysis for Travere Therapeutics.\nThe FDA review extension lands after a choppy few months for Travere’s share price. A 7 day share price return of 5.63% is set against a 30 day share price return decline of 25.73% and a 1 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/assessing-travere-therapeutics-tvtx-valuation-as-fda-extends","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/assessing-travere-therapeutics-tvtx-valuation-as-fda-extends","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TVTX","FSGS","BK4139"],"gpt_icon":0},{"id":"2603618368","title":"Travere Stock Slips After FDA Delays Review Of Key Kidney Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2603618368","media":"Benzinga","labels":["policyRegulatory","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603618368?lang=en_us&edition=fundamental","pubTime":"2026-01-14 19:44","pubTimestamp":1768391082,"startTime":"0","endTime":"0","summary":"Travere Therapeutics&#39; stock declines as FDA extends review of key kidney drug. Q4 sales forecast at $127 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/49900069/travere-stock-slips-after-fda-delays-review-of-key-kidney-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FYX","TVTX","BK4217","SMA","LFSC","FYC","FSGS","BK4139"],"gpt_icon":0},{"id":"2602514796","title":"Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514796?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219200,"startTime":"0","endTime":"0","summary":"Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe plann","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216691/0/en/Apellis-Highlights-Commercial-Execution-and-Strategic-Priorities-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","CHMP","BK4585","LU0106831901.USD","IND","LABU","LU0314104364.USD","LU0225283273.USD","LU0158827781.USD","LU2357305700.SGD","LU0106261372.USD","LU1244550494.USD","LU2347655156.SGD","BK4081","LU2089284900.SGD","BK4137","LU2023251221.USD","LU2133065610.SGD","BK4534","LU0158827948.USD","HCSG","LU0795875169.SGD","EMA","LU1989772840.SGD","LU0128526141.USD","LU0557290698.USD","LU0882574139.USD","LU1732800096.USD","LU1791710400.SGD","LU1720051017.SGD","XLV","LU2028103732.USD","LU1720051108.HKD","XBI","LU0528227936.USD","LU1162221912.USD","BK4516","LU1363072403.SGD","LU0029874061.USD","LU2271345857.HKD","LU0098860793.USD","BK4588","FSGS","LU0234570918.USD","LU0795875086.SGD","LU1732799900.SGD","LU2111349929.HKD","LU0971096721.USD","IE00BZ1G4Q59.USD","BK4087"],"gpt_icon":0},{"id":"2601897000","title":"Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897000","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897000?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704400,"startTime":"0","endTime":"0","summary":"Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction of kidney failureCAMBRIDGE, Mass., Jan.  06, 2026  (GLOBE NEWSWIRE) -- Akebi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213549/37519/en/Akebia-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Praliciguat-for-the-Treatment-of-Focal-Segmental-Glomerulosclerosis-FSGS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","BK4139","AKBA","FSGS"],"gpt_icon":0},{"id":"2588223127","title":"Akebia Announces Establishment of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223127?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196841/37519/en/Akebia-Announces-Establishment-of-Rare-Kidney-Disease-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256331488.USD","MI","PD","FSGS","BK4218","LU2065731478.USD","BK4213","APA","BK4585","RBC","IE00B64QTZ34.USD","BK4181","BK4023","BK4588","BK4157","IE00BLDYK493.USD","LU1169589451.USD","BK4161","BK4077","BK4183","MACE","PK","LU1169590202.USD"],"gpt_icon":0},{"id":"2584757249","title":"ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584757249","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584757249?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587200,"startTime":"0","endTime":"0","summary":"ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3191443/0/en/ZyVersa-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","ZVSA","BK4007","BK4539","FSGS"],"gpt_icon":0},{"id":"2584596023","title":"Dimerix Achieves Positive IDMC Review for Phase 3 FSGS Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584596023","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584596023?lang=en_us&edition=fundamental","pubTime":"2025-11-19 08:48","pubTimestamp":1763513281,"startTime":"0","endTime":"0","summary":"An update from Dimerix Limited ( ($AU:DXB) ) is now available. Dimerix Limited announced the successful completion of the seventh Independent Data ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-achieves-positive-idmc-review-for-phase-3-fsgs-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-achieves-positive-idmc-review-for-phase-3-fsgs-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS"],"gpt_icon":0},{"id":"2582224330","title":"A Look at Travere Therapeutics’s Valuation Following Positive Phase 3 FILSPARI Data in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2582224330","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582224330?lang=en_us&edition=fundamental","pubTime":"2025-11-11 13:27","pubTimestamp":1762838842,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) just released new findings from its Phase 3 DUPLEX Study, showing that FILSPARI treatment helped FSGS patients achieve meaningful reductions in proteinuria compared to the existing standard of care.\nSee our latest analysis for Travere Therapeutics.\nThe excitement from Travere’s Phase 3 DUPLEX Study update comes after a robust rally for the stock, as the one-month share price return surged 36.7% and the 90-day gain climbed to an impressive 90.5%. Adding to the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeuticss-valuation-following-positive-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeuticss-valuation-following-positive-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4007","FSGS","BK4539","BK4139","TVTX"],"gpt_icon":0},{"id":"2581076953","title":"Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2581076953","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581076953?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:02","pubTimestamp":1762498924,"startTime":"0","endTime":"0","summary":"If Dimerix's  US peer Travere's drug Filspari is approved by the US Food and Drug Administration, it would likely be positive for Dimerix, but the consequences would be neutral if rejected, said Euroz Hartleys in a Friday note.The research firm believes that the Filspari launch would raise awareness of focal segmental glomerulosclerosis , improve diagnosis, and establish insurance support for rare kidney disease treatments, and as doctors are expected to use Dimirex's DMX-200 together with Filspari, it could help accelerate acceptance of the medication.If the US FDA rejects Filspari, the effect would likely be neutral for Dimerix, the note added.Euroz Hartleys said that Travere's setback would stem from its trial design, not the medical need. Dimerix's own placebo-controlled study with clear goals follows a stronger regulatory path, keeping its outlook intact.Euroz Hartleys has maintained its speculative buy rating on Dimerix with a price target of AU$1.68.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7501","FSGS","BK7067"],"gpt_icon":0},{"id":"2581779554","title":"Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779554","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581779554?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:15","pubTimestamp":1762352100,"startTime":"0","endTime":"0","summary":"VERO BEACH, Fla., Nov.  05, 2025  (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181589/0/en/Processa-Pharmaceuticals-Announces-Poster-Presentation-of-Adaptive-Phase-2-3-PCS499-Study-in-FSGS-at-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGC","FSGS"],"gpt_icon":0},{"id":"2579170781","title":"Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579170781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579170781?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:05","pubTimestamp":1761822300,"startTime":"0","endTime":"0","summary":"Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI (pegcetacoplan) in the first two months since launch in C3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177251/0/en/Apellis-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1880398471.USD","LU1880398554.USD","LU1852331112.SGD","BK4087","BK4534","LU2054465674.USD","LU0127658192.USD","BK4573","IE0009356076.USD","BK4512","LU1064131342.USD","FSGS","LU1242518931.SGD","LU2458330169.SGD","LU0979878070.USD","LU0642271901.SGD","LU1988902786.USD","BK4141","LU2098885051.SGD","LU1861558580.USD","LU2250418816.HKD","LU0082616367.USD","LU0823434740.USD","LU1803068979.SGD","BK4585","LU0056508442.USD","IE0004445239.USD","LU1303367103.USD","BK4543","IE00B5949003.HKD","LU0109392836.USD","LU1316542783.SGD","LU1951200564.SGD","BK4566","BK4529","LU0889565833.HKD","LU0823434583.USD","LU1951198990.SGD","BK4554","LU2360106780.USD","LU0390134368.USD","LU0823421416.USD","LU0719512351.SGD","EMA","BK4575","LU1242518857.USD","CHMP","LU0823421333.USD"],"gpt_icon":1},{"id":"2577616183","title":"Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2577616183","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577616183?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  22, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171023/0/en/Vera-Therapeutics-to-Host-an-Investor-Call-and-Webcast-to-Provide-an-ORIGIN-3-Update-on-November-6-2025-at-4-30-pm-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJTD4V19.USD","BK4539","LU1718418525.SGD","LU2133065610.SGD","LU1244550494.USD","LU0417517546.SGD","LU0726765562.USD","BK4550","IE00B7KXQ091.USD","BK4581","TACI","FSGS","LU0942090050.USD","LU2347655073.USD","BK4209","LU1585245621.USD","ET","HST","BK4566","BK4218","LU0868494617.USD","BK4561","LU1074936037.SGD","LU0912757837.SGD","MCD","LU0868494708.USD","IE00BJTD4N35.SGD","IE00BFSS7M15.SGD","LU0795875169.SGD","BK4585","BK4534","LU0256863811.USD","BK4181","BK4588","IE00BJJMRX11.SGD","LU1035773651.USD","LU1069347547.HKD","LU1732799900.SGD","BK4610","LU1244550221.USD","IE0004445015.USD","LU0795875086.SGD","LU2279689827.SGD","VERA","LU1430594728.SGD","LU1732800096.USD","IE00BJJMRY28.SGD","IE00BFSS8Q28.SGD","LU2347655156.SGD","BK4144"],"gpt_icon":0},{"id":"2576272059","title":"Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576272059","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576272059?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:12","pubTimestamp":1760706720,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168657/0/en/Vera-Therapeutics-Announces-ORIGIN-3-Late-Breaking-Abstract-Selected-as-Featured-Oral-Presentation-at-Opening-Plenary-Session-of-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7KXQ091.USD","LU1430594728.SGD","LU1035773651.USD","LU1244550577.SGD","LU0256863811.USD","IE00BJJMRY28.SGD","LU0912757837.SGD","IE00BJTD4N35.SGD","IE00BFSS7M15.SGD","IE00BJTD4V19.USD","LU1244550494.USD","LU1732799900.SGD","BK4610","LU0868494708.USD","BK4585","BK4588","BK4209","FSGS","TACI","VERA","LU1585245621.USD","LU0417517546.SGD","LU1732800096.USD","LU2347655156.SGD","MCD","BK4581","LU1244550221.USD","LU2279689827.SGD","LU2133065610.SGD","IE00BFSS8Q28.SGD","LU0795875086.SGD","LU1069347547.HKD","LU0942090050.USD","BK4566","BK4539","BK4534","LU2347655073.USD","IE00BJJMRX11.SGD","LU0726765562.USD","BK4504","BK4139","BK4550","IE0004445015.USD","LU0868494617.USD","LU1074936037.SGD","LU0795875169.SGD","LU1718418525.SGD"],"gpt_icon":0},{"id":"2571336480","title":"Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336480?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:49","pubTimestamp":1759189755,"startTime":"0","endTime":"0","summary":"Dimerix  said its drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis , a serious and rare disease that attacks the kidney, has received Orphan Drug designation in Japan, according to a Tuesday filing with the Australian bourse.Japanese partner FUSO Pharmaceutical Industries has exclusive rights to develop, register, and commercialize DMX-200 to treat FSGS in the Japanese market.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7067","BK7501","FSGS"],"gpt_icon":0},{"id":"2564393460","title":"ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression","url":"https://stock-news.laohu8.com/highlight/detail?id=2564393460","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564393460?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:55","pubTimestamp":1756900500,"startTime":"0","endTime":"0","summary":"ZyVersa is developing Cholesterol Efflux MediatorVAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from ki","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3143489/0/en/ZyVersa-Therapeutics-Highlights-Lipidomic-Data-in-Alport-Syndrome-and-DKD-Reinforcing-the-Need-for-Drugs-to-Attenuate-Damaging-Renal-Lipid-Accumulation-to-Mitigate-Disease-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","ZVSA","FSGS","BK4139"],"gpt_icon":0},{"id":"2564893114","title":"Dimerix's Market Value Falls Despite Full Funding, Record Licensing Deal, Euroz Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2564893114","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564893114?lang=en_us&edition=fundamental","pubTime":"2025-09-01 13:13","pubTimestamp":1756703593,"startTime":"0","endTime":"0","summary":"Dimerix  remained fully funded and in its strongest position to date, yet its market value has fallen by AU$18 million since its record AU$940 million US licensing agreement, Euroz Hartleys said in a report on Monday.Despite receiving AU$48 million in upfront cash and securing up to AU$1.4 billion in potential licensing value across four agreements, the company's shares remain unchanged at around AU$0.45, the same level as a year ago, the broker noted, Euroz said.The company holds enough cash to complete its Phase 3 clinical trial for focal segmental glomerulosclerosis , a rare kidney disease, and could receive up to AU$119 million in development milestone payments and AU$56 million on first US sales within 18 months, along with additional milestone payments from other regions, Euroz added.While the clinical trial risks are still present, the regulatory environment in the US has likely improved, the firm observed.The firm maintained Dimerix's speculative buy rating and its AU$1.68 pric","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","FSGS","BK7067","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2563057684","title":"FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari","url":"https://stock-news.laohu8.com/highlight/detail?id=2563057684","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563057684?lang=en_us&edition=fundamental","pubTime":"2025-08-29 00:40","pubTimestamp":1756399200,"startTime":"0","endTime":"0","summary":"FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/28/Doctor-Utilizing-Advanced-Digital-Tablet.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/28/Doctor-Utilizing-Advanced-Digital-Tablet.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/08/47393162/fda-eases-monitoring-burden-for-kidney-disease-patients-on-travere-therapeutics-filspari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/08/47393162/fda-eases-monitoring-burden-for-kidney-disease-patients-on-travere-therapeutics-filspari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4539","FSGS","EFT","LENZ","BK4007"],"gpt_icon":0},{"id":"2559462489","title":"Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559462489","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559462489?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:01","pubTimestamp":1755028860,"startTime":"0","endTime":"0","summary":"MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3132101/0/en/Maze-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4007","MAZE"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}